Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus

被引：0
|
作者：
Juan Huang
Jun-Xu Gu
Kun Wang
Ai-Min Zhang
Ting-Ting Hong
Shan-Shan Li
Xiao-Qin Yao
Ming Yang
Yue Yin
Na Zhang
Ming Su
Jia-Jia Hu
Xue-Zhi Zhang
Mei Jia
机构：
[1] Peking University International Hospital,Department of traditional Chinese medicine
[2] Peking University People’s Hospital,Department of Clinical Laboratory
[3] Central South University,Department of Clinical Laboratory, Xiangya Hospital
[4] Peking University International Hospital,Department of Clinical Laboratory
来源：
Diabetology & Metabolic Syndrome | / 15卷
关键词：
PCSK9; T2DM; Coronary heart disease; Cardiovascular events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] ASSOCIATION BETWEEN PLASMA LIPIDS, DISEASE ACTIVITY AND PCSK9 LEVELS IN RA PATIENTS
    Heslinga, M.
    Lambert, G.
    Thedrez, A.
    Kastelein, J.
    Nurmohamed, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 259 - 259
  • [42] PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?
    Parhofer, K. G.
    HERZ, 2016, 41 (03) : 217 - 223
  • [43] Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus
    Wilson, SH
    Kennedy, FP
    Garratt, KN
    DRUGS & AGING, 2001, 18 (05) : 325 - 333
  • [44] Predictive nomogram for coronary heart disease in patients with type 2 diabetes mellitus
    Xiao, Shucai
    Dong, Youzheng
    Huang, Bin
    Jiang, Xinghua
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [45] Endothelial dysfunction in patients with coronary heart disease and Type 2 diabetes mellitus
    Petina, M. M.
    Gorokhovskaya, G. N.
    Martynov, A., I
    RUSSIAN JOURNAL OF CARDIOLOGY, 2011, (02): : 32 - 36
  • [46] Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus
    Stephanie H. Wilson
    Frank P. Kennedy
    Kirk N. Garratt
    Drugs & Aging, 2001, 18 : 325 - 333
  • [47] Circulating PCSK9 is associated with pentraxin 3 concentration in patients with type 2 diabetes
    Walus, M.
    Kapusta, M.
    Trojak, A.
    Miarka, P.
    Idzior-Walus, B.
    Malecki, M. T.
    DIABETOLOGIA, 2017, 60 : S569 - S570
  • [48] STRONG ASSOCIATION BETWEEN SERUM PCSK9 AND CARDIOVASCULAR DISEASE IN PATIENTS WITH MODERATE CHRONIC KIDNEY DISEASES THE GCKD STUDY
    Kheirkhah, A.
    Lamina, C.
    Kollerits, B.
    Schachtl-Riess, J. F.
    Schultheiss, U. T.
    Forer, L.
    Sekula, P.
    Ottgen, F. Kotsis A. K.
    Eckardt, K. -U.
    Kronenberg, F.
    ATHEROSCLEROSIS, 2021, 331 : E48 - E48
  • [49] Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
    Bojanin, Dragana
    Vekic, Jelena
    Milenkovic, Tatjana
    Vukovic, Rade
    Zeljkovic, Aleksandra
    Stefanovic, Aleksandra
    Janac, Jelena
    Ivanisevic, Jasmina
    Mitrovic, Katarina
    Miljkovic, Milica
    Spasojevic-Kalimanovska, Vesna
    ATHEROSCLEROSIS, 2019, 280 : 14 - 20
  • [50] Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
    Verges, Bruno
    Hassid, Jonathan
    Rouland, Alexia
    Bouillet, Benjamin
    Simoneau, Isabelle
    Petit, Jean-Michel
    Duvillard, Laurence
    DIABETES & METABOLISM, 2022, 48 (02)
12345